We identified small-molecule dimer disruptors that inhibit an essential dimeric protease of human Kaposi's sarcoma-associated herpesvirus (KSHV) by screening an α-helical mimetic library. Next, we synthesized a second generation of low-micromolar inhibitors with improved potency and solubility. Complementary methods including size exclusion chromatography and 1H-13C HSQC titration using selectively labeled 13C-Met samples revealed that monomeric protease is enriched in the presence of inhibitor. 1H-15N HSQC titration studies mapped the inhibitor binding site to the dimer interface, and mutagenesis studies targeting this region were consistent with a mechanism where inhibitor binding prevents dimerization through the conformational selection of a dynamic intermediate. These results validate the interface of herpesvirus proteases and other similar oligomeric interactions as suitable targets for the development of small-molecule inhibitors.
|Number of pages||7|
|Journal||Nature Chemical Biology|
|State||Published - Sep 2009|
Bibliographical noteFunding Information:
The authors thank W. Gibson (The Johns Hopkins University School of Medicine) for providing us with the CMV protease expression plasmid and for valuable feedback on the manuscript. This work was funded by US National Institutes of Health grants T32 GMO7810 and AIO67423 (C.S.C.) and by the American Lebanese and Syrian Associated Charities and the St. Jude Children’s Research Hospital (R.K.G.). We also thank the University of California, San Francisco–Gladstone Institute for Virology and Immunology/Center for AIDS Research for the Clinical Science Pilot Award (P30-AI027763 to G.M.L.).
ASJC Scopus subject areas
- Molecular Biology
- Cell Biology